"10.1371_journal.pone.0132055","plos one","2015-07-15T00:00:00Z","Kazuko Uno; Kazuyuki Yoshizaki; Mitsuhiro Iwahashi; Jiro Yamana; Seizo Yamana; Miki Tanigawa; Katsumi Yagi","Department of Organic Fine Chemicals, Division of Biological and Molecular Sciences, The Institute of Scientific and Industrial Research, Osaka University, Suita, Osaka, Japan; Louis Pasteur Center for Medical Research, Kyoto, Kyoto, Japan; Higashi Hiroshima Memorial Hospital, Higashi Hiroshima, Hiroshima, Japan; Tokushukai Medical Corporation, Tokyo, Japan","Conceived and designed the experiments: KU K. Yoshizaki. Performed the experiments: KU MT. Analyzed the data: KU K. Yagi MI. Contributed reagents/materials/analysis tools: KU. Wrote the paper: KU K. Yoshizaki. Recruited participants and collected data: JY SY MI. Created patients’ database: MT.","Kazu Yo has received speaking fees from Chugai Pharmaceutical Co. and is the co-inventor of tocilizumab treatment for Still’s disease. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","07","Kazuko Uno","KU",7,TRUE,2,2,2,2,TRUE,TRUE,FALSE,0,NA,FALSE
